| __timestamp | Bausch Health Companies Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 9136000 |
| Thursday, January 1, 2015 | 2645000000 | 5807000 |
| Friday, January 1, 2016 | 2611000000 | 5571000 |
| Sunday, January 1, 2017 | 2548000000 | 5366000 |
| Monday, January 1, 2018 | 2351000000 | 6337000 |
| Tuesday, January 1, 2019 | 2350000000 | 11347000 |
| Wednesday, January 1, 2020 | 2249000000 | 30419000 |
| Friday, January 1, 2021 | 2394000000 | 62176000 |
| Saturday, January 1, 2022 | 2364000000 | 52827000 |
| Sunday, January 1, 2023 | 2559000000 | 35049000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Bausch Health Companies Inc. and Ligand Pharmaceuticals Incorporated present a fascinating study in contrasts over the past decade. From 2014 to 2023, Bausch Health's cost of revenue has shown a relatively stable trend, peaking in 2015 with a 17% increase from the previous year, before settling into a consistent range. In contrast, Ligand Pharmaceuticals has experienced a more volatile journey, with a staggering 580% increase in cost of revenue from 2014 to 2021, reflecting its strategic shifts and market adaptations.
This data not only highlights the operational strategies of these companies but also underscores the broader economic forces at play. As the pharmaceutical landscape continues to shift, these insights offer a window into the financial health and strategic priorities of industry leaders.
Cost of Revenue: Key Insights for Eli Lilly and Company and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Bausch Health Companies Inc.
Amgen Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Sanofi vs Bausch Health Companies Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses